Understanding Clinical Trial Phases, Study Status, and Timelines
A reference guide to the phase system, ClinicalTrials.gov status labels, and the practical realities for access
When a Trial Watch post says a drug is in Phase 2, or that a trial is “active, not recruiting,” those phrases carry specific meaning. This guide explains the clinical trial phase system and ClinicalTrials.gov status labels so patients following the pipeline can interpret what they’re reading.
The phase system
Clinical trials move through phases in sequence. Each phase asks a different question, involves a different number of participants, and sits a different distance from patient access.
Preclinical
Before a drug enters human trials, it’s tested in laboratory and animal models. Preclinical research can establish whether a drug does something biologically useful and whether it appears safe enough to test in humans. It cannot establish that a drug works in people.
Preclinical findings generate genuine interest, and they’re worth knowing about as context. They are also the stage farthest from patient access, often a decade or more away, if the drug gets there at all. Most drugs that look promising preclinically don’t make it through human trials.
What it means for patients: Background only. Not relevant to treatment decisions or near-term possibilities.
Phase 1
Phase 1 is the first time a drug is tested in humans. The primary question is safety: Is this drug tolerable? What doses cause side effects? What does the body do with it? Phase 1 trials are typically small, with typically 20 to 80participants, and are not designed to establish whether the drug works. Some Phase 1 trials enroll healthy volunteers; others enroll patients, particularly in disease areas where the drug has no other plausible application.
What it means for patients: Years away from approval if everything goes right. File as background.
Phase 2
Phase 2 trials test whether there’s a meaningful signal that the drug does something useful, in a defined patient population, at doses established in Phase 1. They’re larger than Phase 1, with typically a few hundred participants, but still not large enough to be definitive. A Phase 2 success means researchers have enough evidence of potential benefit to justify the larger investment of a Phase 3 trial. It does not mean the drug works. Many drugs that succeed in Phase 2 fail in Phase 3 when tested more rigorously in a larger population.
Phase 2 is also where results include disease activity scores, patient-reported outcomes, and other endpoints that research coverage reports on. A strong Phase 2 signal is worth watching, but it’s not a reason to expect access soon.
What it means for patients: A promising signal but significant uncertainty. Worth watching, not waiting for.
Phase 3
Phase 3 is the pivotal stage. These large, rigorous trials generate the evidence base for regulatory approval, typically involving hundreds to thousands of participants over an extended timeline. A Phase 3 success means the drug has demonstrated efficacy and an acceptable safety profile in a setting large enough to be credible. Regulatory submission is likely to follow, though approval is not guaranteed.
Phase 3 is also the most relevant stage for patients considering trial participation, as eligibility criteria are broad enough to include a meaningful range of patients.
What it means for patients: Phase 3 is where findings begin to be relevant to treatment considerations. If the trial is still recruiting, it’s a candidate for the participation questions in the companion guide. If results are posted, the regulatory timeline is one to follow.
FDA Submission and Review
Once the FDA decides the application is complete enough to review (a step often called “filing,” usually within about 60 days of submission), the official review clock begins. For most drugs, the FDA’s goal is to complete a standard review in about 10 months from this filing date. Some applications qualify for priority review, which has a shorter goal of about 6 months. A faster review goal does not guarantee that the drug will be approved, but it does mean the FDA aims to make a decision sooner.
Certain programs, such as Breakthrough Therapy designation, are designed to help promising treatments for serious conditions move through development more quickly. These programs can give companies earlier and more frequent contact with the FDA and may allow them to submit parts of their application as they are ready (sometimes called rolling review). Even so, once the full application is filed, these special designations do not change the formal FDA review timelines.
Throughout the process, the FDA may request additional information, which can extend the timeline. Even after a successful Phase 3 trial, the FDA can decline approval or request more data. If that happens, the sponsor receives a Complete Response Letter explaining what’s needed before the application can be reconsidered.
What it means for patients: Approval is six to eighteen months away if review proceeds without complications. A good time to start understanding what access might look like. “How Biologic Drug Access Works” can be a useful reference here.
Approved (limited access)
Note: “Limited access” isn’t a formal FDA category; it instead describes a practical reality that affects most newly approved biologics.
FDA approval means the agency has determined a drug is safe and effective for a defined use in a specific patient population. It does not mean the drug is immediately accessible.
Insurance coverage decisions, formulary placement, step therapy requirements, and specialty pharmacy contracting all happen after approval, on timelines the FDA doesn't control. A drug can be approved and still functionally inaccessible while that infrastructure catches up.
This is particularly relevant for autoimmune conditions, where payers may impose step therapy requirements that weren’t part of the trial criteria, and where established treatment ladders don’t exist for some conditions.
What it means for patients: The drug exists, but whether you can access it depends on your insurance coverage, treatment history, and your insurer’s requirements. Understanding Biologic Drug Access covers this in detail.
Approved (Accessible)
The drug is approved and, for most patients with appropriate insurance and disease profile, reachable through standard care. This is a conversation to have with your rheumatologist about your eligibility, treatment history, and your insurer’s requirements.
What it means for patients: Talk with your rheumatologist about whether this medication is a good fit for you and how to get it. The drug is available, but your insurance or health system may have specific steps you need to go through.
ClinicalTrials.gov Status: What the Labels Mean
Every registered clinical trial has a status on ClinicalTrials.gov that updates as the trial progresses.
Recruiting: The trial is open and actively enrolling participants. Patients who meet the eligibility criteria and can access the trial location may consider participation. Contact the listed trial coordinator for information about eligibility screening.
Active, Not Recruiting: The trial is ongoing but has reached its target enrollment. New patients cannot join; watch for results.
Enrolling by Invitation: Only participants who have been specifically invited can join—typically patients already known to the research team or participants from a related prior study. Not open to general inquiry.
Completed: All participants have finished treatment and follow-up. All participants have finished treatment and follow-up. Results may or may not be posted to the “Results” tab on the ClinicalTrials.gov listing. “Results Posted” indicates that summary data has been submitted; peer-reviewed publication typically follows months to years later.
Terminated: The trial was stopped before completion. Termination can happen for multiple reasons: a safety signal, a business decision by the sponsor, insufficient enrollment, or an interim analysis showing the drug is unlikely to succeed. The reason for termination is sometimes disclosed in the registry and sometimes not. Termination is not the same as failure, though it often means the drug’s development has stalled or ended.
Withdrawn: The trial was stopped before any participants were enrolled, typically reflecting a sponsor decision made before recruitment began.
Unknown: The trial’s status has not been updated within the required timeframe, which may mean the trial is ongoing with an overdue update.
How The Pieces Connect
These guides cover the full arc from early research to patient access. This one covers trial phases and status labels. A Patient’s Guide to Clinical Trial Participation: Part 1 addresses the questions to weigh before joining a trial. A Patient’s Guide to Clinical Trials, Part 2 covers what the experience actually involves. Understanding Biologic Drug Access picks up after approval. Read them in whatever order is useful; none requires reading the others first.
References and further reading
On trial phases
ClinicalTrials.gov: Learn About Studies. The registry’s own plain-language explanation of trial phases, study types, and what each stage involves.
FDA: The Drug Development Process. A step-by-step overview of how a drug moves from laboratory to approval, written for a general audience.
On eligibility criteria and finding trials
ClinicalTrials.gov. The primary public registry of clinical trials, searchable by condition, location, phase, and recruitment status.
FDA: Finding Clinical Trials. Patient-oriented guidance on how to search for and evaluate trial opportunities.
Corrections and clarifications always welcome: kelly@theconnectivethread.com.
The Connective Thread is written by a patient, not a clinician. Nothing here is medical advice.